Adley Brian P, Gupta Anita, Lin Fan, Luan Chunyan, Teh Bin T, Yang Ximing J
Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.
Am J Clin Pathol. 2006 Jul;126(1):79-85. doi: 10.1309/JFE2-B57Y-QFPW-PL10.
Kidney-specific cadherin (Ksp-cad) recently was proposed to differentiate chromophobe renal cell carcinoma (RCC) from oncocytoma based on a finding of Ksp-cad expression in 97% of chromophobe RCCs but only 3% of oncocytomas. However, another study showed no difference in Ksp-cad immunoreactivity between these 2 tumors. We attempted to evaluate Ksp-cad expression in renal tumors using expression microarrays and immunohistochemical analysis. Ksp-cad messenger RNA (mRNA) levels were examined in 158 renal tumors, including 15 chromophobe RCCs and 15 oncocytomas. Immunohistochemical analysis was performed on tissue microarrays containing 125 renal tumors, including 36 chromophobe RCCs and 41 oncocytomas. Ksp-cad mRNA compared with normal kidney tissue was 89% in chromophobe RCC and 64% in oncocytoma. Furthermore, 31 of 36 chromophobe RCCs and 31 of 41 oncocytomas showed Ksp-cad immunoreactivity. Ksp-cad was present in chromophobe RCCs and oncocytomas at mRNA and protein levels, providing strong evidence that Ksp-cad immunohistochemical analysis cannot be used in differentiating these tumors.
肾特异性钙黏蛋白（Ksp-cad）最近被提出可用于鉴别嫌色性肾细胞癌（RCC）和嗜酸细胞瘤，这是基于一项发现，即97%的嫌色性RCC表达Ksp-cad，而只有3%的嗜酸细胞瘤表达。然而，另一项研究表明这两种肿瘤之间Ksp-cad免疫反应性没有差异。我们试图使用表达微阵列和免疫组织化学分析来评估肾肿瘤中Ksp-cad的表达。在158例肾肿瘤中检测了Ksp-cad信使核糖核酸（mRNA）水平，包括15例嫌色性RCC和15例嗜酸细胞瘤。对包含125例肾肿瘤的组织微阵列进行了免疫组织化学分析，其中包括36例嫌色性RCC和41例嗜酸细胞瘤。与正常肾组织相比，嫌色性RCC中Ksp-cad mRNA为89%，嗜酸细胞瘤中为64%。此外，36例嫌色性RCC中的31例和41例嗜酸细胞瘤中的31例显示出Ksp-cad免疫反应性。Ksp-cad在嫌色性RCC和嗜酸细胞瘤中均以mRNA和蛋白质水平存在，这有力地证明了Ksp-cad免疫组织化学分析不能用于鉴别这些肿瘤。
